A new weight-loss medication, Wegovy, is being released in the United Kingdom starting today, marking a significant development in obesity treatment. The drug, available in tablet form, is the first oral medication of its kind approved by the UK medicines regulator for weight management. Manufactured by Danish pharmaceutical company Novo Nordisk, Wegovy tablets will be sold privately at prices ranging from £79 to £100 per month. Some pharmacies have already reported substantial demand, with one online provider pre-approving orders for around 10,000 customers.
Wegovy operates as a GLP-1 receptor agonist and offers an alternative to injectable weight-loss drugs, such as Mounjaro and semaglutide formulations already available on the NHS for certain patients. Its convenience as a daily pill—plus not requiring refrigeration—may particularly appeal to individuals who have difficulty with injections or prefer oral medication. Initial treatment begins at 1.5mg daily with doses increasing over time up to 25mg.
While hailed by some healthcare professionals as potentially “transformational,” the drug is currently only accessible through private prescriptions, as it has not yet received approval for use by the National Health Service (NHS). Experts estimate that NHS availability could take 18 months to two years, following review by the National Institute for Health and Care Excellence (NICE). This delay has raised concerns among healthcare advocates that a “two-tier” system may emerge, where only those able to afford private prescriptions can access the medication while others must wait.
Patient groups and healthcare providers emphasize that obesity is a complex, chronic medical condition requiring comprehensive management. Olivier Picard, chair of the National Pharmacy Association, highlighted that the tablets provide additional treatment options but cautioned that weight-loss drugs are not suitable for everyone and should be prescribed responsibly. There are warnings against purchasing medication from unverified sources to avoid counterfeit products, a danger exacerbated by the ease of pill distribution.
Concerns have also been voiced about the potential for misuse of the medication by individuals without clinical need, particularly for cosmetic weight loss. NHS England’s former director Stephen Power and other experts have noted instances of non-obese people seeking these treatments for appearance-related reasons. Healthcare leaders stress that any future NHS rollout would need to be carefully managed and properly resourced to ensure medications are prescribed based on clinical guidelines.
The launch of Wegovy tablets underscores ongoing challenges in addressing obesity at both clinical and societal levels, balancing patient access, safety, cost, and equitable healthcare provision. Meanwhile, pharmacies across the UK are preparing for a surge in demand, reflecting growing interest in new medical approaches to weight management.